Big pat on the back from Danish drug discovery company
Danish drug discovery company BioImage has turned to NCE Discovery to increase its library of compounds to screen against targets using Redistribution technology.
This technology monitors the translocation of proteins in live cells in real time and BioImage is specifically using it to help discover small molecule drugs that affect the translocation process.
Ivan Mikkelsen, chemistry manager at BioImage, explained: "Redistribution technology can be used by anybody with a microscope, but our operation is unique because we have applied the technique to high throughput screening." Christian Krog-Jensen, manager of medicinal chemistry at BioImage, continued: "Our company is quite new to drug discovery and development and we needed to increase our in-house library of compounds to be able to screen for the different types of targets in which we are interested. There are about 2.6 million compounds on the market and NCE Discovery was able to identify 220,000 meeting our specifications that we should purchase which increased our compound library from 60,000 to 280,000 compounds." Ivan concluded: "When we first contacted NCE Discovery, we immediately felt that these were people we could speak to, who understood what we needed, and we really felt we could work together.
It has been a very fruitful arrangement and I really like the attitude of NCE Discovery.
It is a user-friendly company."
